Display options
Cite
Cunnea P, Gowers S, Moore JE, et al. Review article: Novel technologies in the treatment and monitoring of advanced and relapsed epithelial ovarian cancer. Converg Sci Phys Oncol. 2017;3doi: 10.1088/2057-1739/aa5cf1.
Cunnea, P., Gowers, S., Moore, J. E., Drakakis, E., Boutelle, M., & Fotopoulou, C. (2017). Review article: Novel technologies in the treatment and monitoring of advanced and relapsed epithelial ovarian cancer. Convergent science physical oncology, 3. https://doi.org/10.1088/2057-1739/aa5cf1
Cunnea, Paula, et al. "Review article: Novel technologies in the treatment and monitoring of advanced and relapsed epithelial ovarian cancer." Convergent science physical oncology vol. 3 (2017). doi: https://doi.org/10.1088/2057-1739/aa5cf1
Cunnea P, Gowers S, Moore JE, Drakakis E, Boutelle M, Fotopoulou C. Review article: Novel technologies in the treatment and monitoring of advanced and relapsed epithelial ovarian cancer. Converg Sci Phys Oncol. 2017;3. doi: 10.1088/2057-1739/aa5cf1. Epub 2017 Feb 23. PMID: 29515912; PMCID: PMC5837061.
Copy Download .nbib Format: NLM
Share it on

Converg Sci Phys Oncol. 2017;3. doi: 10.1088/2057-1739/aa5cf1. Epub 2017 Feb 23.

Review article: Novel technologies in the treatment and monitoring of advanced and relapsed epithelial ovarian cancer.

Convergent science physical oncology

Paula Cunnea, Sally Gowers, James E Moore, Emmanuel Drakakis, Martyn Boutelle, Christina Fotopoulou

Affiliations

  1. Department of Surgery and Cancer, Imperial College London.
  2. Department of Bioengineering, Imperial College London.

PMID: 29515912 PMCID: PMC5837061 DOI: 10.1088/2057-1739/aa5cf1

Abstract

Epithelial Ovarian cancer (EOC) is the fifth most common cause of cancer death in females in the UK. It has long been recognized to be a set of heterogeneous diseases, with high grade serous being the most common subtype. The majority of patients with EOC present at an advanced stage (FIGO III-IV), and have the largest risk for disease recurrence from which a high percentage will develop resistance to chemotherapy. Despite continual advances in diagnostics, imaging, surgery and treatment of EOC, there has been little variation in the survival rates for patients with EOC. In this review we will introduce novel bioengineering advances in modelling the lymphatic system and real-time tissue monitoring to improve the clinical and therapeutic outcome for patients with EOC. We discuss the advent of the non-invasive "liquid biopsy" in the surveillance of patients undergoing treatment and follow-up. Finally, we present new bioengineering advances for palliative care of patients to lessen symptoms of patients with ascites and improve quality of life.

Conflict of interest statement

We declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Crit Rev Oncol Hematol. 2013 Nov;88(2):338-56 - PubMed
  2. Proc Natl Acad Sci U S A. 2009 Jul 28;106(30):12459-64 - PubMed
  3. BMC Med. 2016 Aug 24;14 (1):126 - PubMed
  4. Sci Transl Med. 2014 Feb 19;6(224):224ra24 - PubMed
  5. Gynecol Oncol. 2007 Jun;105(3):801-12 - PubMed
  6. Gynecol Oncol. 2014 Sep;134(3):581-90 - PubMed
  7. Int J Gynecol Cancer. 2009 Dec;19 Suppl 2:S63-7 - PubMed
  8. PLoS One. 2015 Dec 30;10(12):e0145754 - PubMed
  9. Cancer. 2009 Mar 15;115(6):1234-44 - PubMed
  10. Eur J Cancer. 2012 Mar;48(5):687-94 - PubMed
  11. Sci Transl Med. 2013 Jul 17;5(194):194ra93 - PubMed
  12. Lancet. 2010 Oct 2;376(9747):1155-63 - PubMed
  13. Anal Bioanal Chem. 2013 Apr;405(11):3881-8 - PubMed
  14. Annu Rev Anal Chem (Palo Alto Calif). 2013;6:427-53 - PubMed
  15. Sci Transl Med. 2012 May 30;4(136):136ra68 - PubMed
  16. Gynecol Oncol. 2008 Apr;109(1):129-39 - PubMed
  17. Gynecol Oncol. 2013 Nov;131(2):352-6 - PubMed
  18. Cancer Res. 2001 Feb 15;61(4):1659-65 - PubMed
  19. Am J Cancer Res. 2016 May 01;6(5):973-80 - PubMed
  20. Clin Cancer Res. 2017 May 1;23 (9):2213-2222 - PubMed
  21. Nat Rev Cancer. 2006 Feb;6(2):107-16 - PubMed
  22. Int J Nanomedicine. 2013;8:2247-57 - PubMed
  23. J Clin Oncol. 2013 Jun 20;31(18):2273-81 - PubMed
  24. Clin Chim Acta. 2014 Jun 10;433:69-75 - PubMed
  25. Sci Transl Med. 2015 Apr 22;7(284):284ra57 - PubMed
  26. Sci Transl Med. 2015 Apr 22;7(284):284ra58 - PubMed
  27. Sci Transl Med. 2012 Nov 28;4(162):162ra154 - PubMed
  28. Am J Pathol. 2016 Aug;186(8):2193-2203 - PubMed
  29. PLoS One. 2015 Jun 22;10(6):e0130873 - PubMed
  30. Dis Colon Rectum. 2008 Sep;51(9):1408-13 - PubMed
  31. Gynecol Oncol. 1992 Nov;47(2):203-9 - PubMed
  32. Gynecol Oncol. 2013 Jan;128(1):1-2 - PubMed
  33. Gut. 2016 Apr;65(4):625-34 - PubMed
  34. ACS Chem Neurosci. 2013 May 15;4(5):799-807 - PubMed
  35. J Clin Oncol. 2005 Mar 1;23(7):1420-30 - PubMed
  36. Circulation. 2008 Sep 30;118(14 Suppl):S16-23 - PubMed
  37. Gynecol Oncol. 2013 Jan;128(1):15-21 - PubMed
  38. BMC Cancer. 2010 Dec 03;10 :666 - PubMed
  39. Clin Obstet Gynecol. 2012 Mar;55(1):36-42 - PubMed
  40. Sci Transl Med. 2015 Apr 22;7(284):284ps10 - PubMed
  41. Anal Chim Acta. 2009 Sep 28;651(1):1-14 - PubMed
  42. Int J Gynecol Cancer. 2007 Nov-Dec;17(6):1238-44 - PubMed
  43. Histopathology. 2013 Jan;62(1):44-58 - PubMed
  44. Diabetes Technol Ther. 2013 Jan;15(1):101-15 - PubMed
  45. Bull Math Biol. 2016 Jan;78(1):52-71 - PubMed
  46. Anal Chem. 2006 Mar 1;78(5):1391-9 - PubMed
  47. Gynecol Oncol. 2010 Sep;118(3):210-1 - PubMed
  48. J Surg Res. 2016 Jan;200(1):332-45 - PubMed
  49. Nat Rev Cancer. 2009 Apr;9(4):274-84 - PubMed
  50. Neoplasia. 2014 Jan;16(1):97-103 - PubMed
  51. Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:11-7 - PubMed
  52. Clin Cancer Res. 2007 Dec 1;13(23):7053-8 - PubMed
  53. Lancet Oncol. 2012 Nov;13(11):1114-24 - PubMed
  54. Eur J Surg Oncol. 2016 Dec;42(12 ):1772-1779 - PubMed
  55. Nat Rev Cancer. 2011 Sep 23;11(10):719-25 - PubMed
  56. Clin Cancer Res. 2016 Jun 15;22(12 ):3097-3104 - PubMed
  57. Eur J Surg Oncol. 2009 Feb;35(2):135-43 - PubMed
  58. Lymphat Res Biol. 2015 Dec;13(4):234-47 - PubMed
  59. Clin Cancer Res. 2004 Jul 1;10 (13):4420-6 - PubMed
  60. Nature. 2013 May 2;497(7447):108-12 - PubMed
  61. J Clin Oncol. 2002 Mar 1;20(5):1248-59 - PubMed
  62. Arch Gynecol Obstet. 2015 Jul;292(1):231-4 - PubMed
  63. Analyst. 2016 Oct 24;141(22):6270-6277 - PubMed
  64. Annu Rev Anal Chem (Palo Alto Calif). 2008;1:627-61 - PubMed
  65. Gynecol Oncol. 2011 Jan;120(1):113-20 - PubMed
  66. Cancer. 1986 May 1;57(9):1725-30 - PubMed
  67. CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 - PubMed
  68. Cancer Discov. 2011 Dec;1(7):580-6 - PubMed
  69. Sci Rep. 2016 Jul 20;6:29831 - PubMed

Publication Types

Grant support